KING OF PRUSSIA, PA, January 20, 2010 – MDS Pharma Services, a leading provider of innovative drug discovery and early stage development solutions, has adopted SAS Drug Development to provide a centralized, integrated system for managing, analyzing, reporting and reviewing clinical research data.
SAS Drug Development technology has been implemented across MDS Pharma Services from the pre-clinical line of business through Phase IIa to integrate worldwide work flows. The software provides seamless integration and traceability from data capture through submission; it also expedites conversion of data into formats established by the Clinical Data Interchange Standards Consortium (CDISC) for electronic New Drug Application submissions and the Clinical Data Acquisition Standards Harmonization (CDASH) for compliant electronic case report forms.
“This powerful tool vastly improves our internal operational efficiency and enhances our ability to provide high quality, on-time service to clients,” said MDS Pharma Services President David Spaight. “The advantages of improved data integrity and expedited access to study data are available to all our clients, but are significantly magnified in the case of clients who also operate on the SAS Drug Development technology platform. Sponsors on the SAS Drug Development platform have found that we can collaborate more efficiently and effectively, and at a reduced cost thanks to faster data sharing.”
Through tightly integrated SAS Drug Development systems, MDS Pharma Services can provide similarly equipped sponsor organizations with immediate access to their clinical trial data for faster decision making. Users at both organizations are automatically notified when new content is available, and the system’s ability to thoroughly document the history of each content object increases trust between the two organizations. Each system fully documents not only the current version of the content, but all previous versions as well.
This 21st century approach to collaboration and information sharing in clinical research allows for data transfers that are well-controlled, automated and seamless.
“When sponsor and CRO work together across the shared and managed SAS technology infrastructure, they experience a tremendous leap in data sharing and review that is not possible in the world of file transfer protocol (FTP) downloads and overnight deliveries, ” said David Handelsman, Business Solutions Manager, Life Sciences Research and Development, at SAS. “The success that MDS Pharma Services has achieved via the collaborative capabilities of SAS Drug Development serves as a model for how sponsors and CROs can take their business relationship to the next level.”
About SAS® Drug Development
SAS Drug Development provides a centralized, integrated system for managing, analyzing, reporting and reviewing clinical research information. The solution enables life sciences organizations to get products to market faster by more effectively assessing the safety and efficacy of research compounds. The solution also facilitates collaboration across trials, phases and therapeutic areas.
SAS Drug Development is a Part 11-compliant data storage repository that utilizes SAS 9.2 – the leading analytics platform. New SAS versions bring a wealth of additional capabilities that enable MDS Pharma Services to meet each client’s evolving needs with a world-class array of technology and powerful analytics.
More Information
Additional information with respect to MDS Pharma Services’ new strategic focus on Early Stage Operations (Discovery through Phase IIa) can be found on MDS Inc.’s Website at
www.mdsinc.com/for_media/electronic_media_kit.asp.
About MDS Pharma Services
MDS Pharma Services, a business unit of MDS Inc., is committed to delivering quality service on time. We offer a full spectrum of resources to meet the needs of the pharmaceutical and biotechnology industries from Discovery through Phase IIa proof-of-concept studies. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the early phases of drug discovery and development – from lead identification and optimization, pre-investigational new drug (IND) research, early clinical research (bioequivalence, Phases 0-IIa, clinical pharmacology, bioanalysis and early cardiac testing). For more information, visit our Web site at www.mdsps.com.
